注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
諾誠健華醫藥有限公司是一家主要從事生物醫藥研發、生產和商業化的中國公司。該公司專注於腫瘤和自身免疫性疾病等存在巨大未滿足臨床需求的領域。該公司的主要產品管線包括奧布替尼、伊布替尼、澤布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-192、ICP-723和ICP-189等。其產品主要用於治療血液瘤、實體瘤和自身免疫病。該公司還在開髮用於治療由B細胞或T細胞功能異常所導致的自身免疫性疾病的產品。該公司主要在國內和國外市場開展業務。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Lan Hu | 49 | 2020 | Independent Non-Executive Director |
Yigong Shi | 54 | 2015 | Non-Executive Director & President of Scientific Advisory Board |
Renbin Zhao | 54 | 2015 | VP of Regulatory Affairs & Clinical Development and Executive Director |
Jisong Cui | 60 | 2015 | Co-Founder, Chairwoman & CEO |
Arnold J. Levine | 83 | - | Member of Scientific Advisory Board |
Kaixian Chen | 77 | 2020 | Independent Non-Executive Director |
Zemin Zhang | 55 | 2015 | Member of Scientific Advisory Board |
Zhanguo Li | - | - | Member of Scientific Advisory Board |
Ronggang Xie | 37 | 2021 | Non-Executive Director |
Ming Jin | 49 | 2022 | Non-Executive Director |
Dandan Dong | 39 | 2023 | Independent Non-Executive Director |
James Deng | - | - | Member of Scientific Advisory Board in Sales & Marketing |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核